tumorassoci
antigen
taa
attract
candid
cancer
therapi
view
specif
tumor
target
safeti
profil
although
known
tumor
antigen
gener
cancerspecif
immun
respons
either
poorli
immunogen
function
nonimmunogen
may
elicit
immun
respons
suffici
erad
tumor
cell
therefor
effort
enhanc
taamedi
host
immun
toward
tumor
made
explor
varieti
adjuv
immunotherapi
adjuv
cancer
vaccin
highlyimmunogen
vector
combin
tcell
costimulatori
molecul
immunestimulatori
cytokin
usual
employ
carcinoembryon
antigen
cea
wellknown
overexpress
taa
human
colon
carcinoma
vaccin
cea
demonstr
induc
although
minor
effect
humor
tcell
respons
order
magnifi
ceamedi
tumorspecif
immun
activ
coadministr
cea
immunerespons
enhanc
granulocytemacrophag
colonystimul
factor
gmcsf
interleukin
il
yield
promis
result
regard
activ
cellular
humor
ceaspecif
immun
respons
antigen
peptid
deriv
sever
acut
respiratori
syndrom
coronaviru
sarscov
exhibit
strong
immunogen
specif
immunogen
epitop
protein
sarscov
demonstr
exhibit
vigor
affin
toward
bind
induc
high
level
gamma
interferon
secret
tcell
therefor
employ
highlyimmunogen
peptid
may
boost
posit
properti
cea
tumor
vaccin
studi
construct
fusion
gene
fuse
partial
sequenc
cea
highlyimmunogen
fragment
sarscov
verifi
consist
effect
elicit
secret
human
achiev
simpl
administr
drug
enhanc
host
immun
oral
dna
vaccin
vector
salmonella
typhimurium
use
carrier
deliv
sarscovcea
fusion
gene
use
method
sought
demonstr
administr
custom
effici
cancer
therapi
combin
select
taa
immuneactiv
sequenc
use
simpl
drugdeliveri
method
signific
retard
tumor
growth
increas
surviv
observ
mice
cancer
studi
result
obtain
use
strategi
therefor
promis
syfpeithi
predict
algorithm
use
predict
interact
affin
calcul
find
lowimmunogen
taa
prevent
human
taa
activ
mous
immun
truncat
cea
peptid
use
lowimmunogen
tumor
antigen
studi
sequenc
shown
figur
cea
sequenc
predict
less
immunogen
affin
calcul
highest
epitop
score
cea
aa
figur
epitop
score
far
lower
score
wellknown
epitop
listeria
monocytogen
listeriolysin
epitop
score
epitop
score
tabl
select
sar
fragment
fuse
cea
sequenc
shown
figur
describ
previous
epitop
within
ceasarscov
amino
acid
sequenc
also
calcul
compar
known
epitop
listeria
monocytogen
result
highest
score
within
ceasar
sequenc
sar
region
tabl
lower
score
known
epitop
l
monocytogen
interact
addit
fusion
cea
sar
sequenc
creat
new
epitop
higher
score
data
shown
examin
cytokin
profil
differ
immun
group
quantit
sera
sampl
collect
group
week
vaccin
ie
week
tumor
inocul
cytokin
repres
detect
elisa
pceasarscov
group
reveal
significantli
higher
product
pcea
control
group
p
figur
determin
efficaci
pceasarscov
tumor
vaccin
mice
oral
immun
pcea
pceasarscovtransform
typhimurium
day
inocul
colon
cancer
cell
per
data
shown
figur
tumor
volum
significantli
lower
pceasarscov
group
p
compar
pcea
group
indic
sar
fragment
provid
suffici
protect
develop
tumor
regard
therapeut
effect
vaccin
mice
inocul
day
later
oral
immun
typhimurium
transform
pcea
pceasarscov
pb
neg
control
group
fed
pb
therapi
pcea
abl
induc
respons
reduc
growth
tumor
comparison
control
group
mice
ceasarscov
group
exhibit
significantli
less
tumor
growth
indic
sar
fragment
provid
adequ
protect
figur
p
comparison
control
pcea
group
result
demonstr
fusion
peptid
compos
highlyimmunogen
epitop
poorlyimmunoreact
tumorassoci
antigen
effect
activ
host
immun
furthermor
use
predict
algorithm
syfpeithi
enhanc
affin
antigen
present
result
fusion
peptid
provok
even
stronger
immun
respons
addit
studi
also
provid
new
insight
tumorspecif
immun
combin
sarscov
epitop
tumor
unrel
antigen
fragment
cea
final
demonstr
could
promis
anticanc
strategi
effect
increas
cytokin
decreas
tumor
volum
dna
vaccin
though
usual
inject
intramuscularli
administ
oral
anim
model
bacteria
observ
display
preferenti
replic
preferenti
accumul
tumor
microenviron
among
bacteria
typhimurium
one
util
carri
therapeut
transgen
attenu
typhimurium
partial
gene
modif
affect
abil
achiev
high
tumornorm
tissu
ratio
mous
model
bacteria
maintain
capac
inhibit
growth
subcutan
tumor
lung
metastat
diseas
modif
also
report
exampl
strain
use
studi
attenu
aromat
aciddepend
aro
typhimurium
wellcharacter
carrier
variou
heterogen
antigen
vaccin
strain
capabl
colon
gutassoci
lymphoid
tissu
peyer
patch
secondari
lymphat
tissu
includ
spleen
liver
follow
oral
administr
mice
elicit
mucos
humor
cellmedi
immun
respons
previou
studi
proven
lipopolysaccharid
salmonella
surfac
enabl
monocyt
secret
also
typhimurium
could
deliv
directli
cytosol
macrophag
dendrit
cell
result
vigor
antigenspecif
cell
prime
induct
protect
immun
virus
bacteria
tumor
variat
cytokin
profil
aros
vaccin
pceasarscov
highlyimmunogen
peptid
treatment
sarscontain
epitop
elicit
strike
increas
express
compar
neg
control
cea
group
figur
proinflammatori
cytokin
indic
austin
colleagu
use
defin
cytotox
lymphocyt
effector
popul
reduc
local
express
found
associ
melanoma
outgrowth
mice
sc
administr
significantli
suppress
primari
tumor
growth
melanoma
typic
cytokin
enhanc
pceasarscov
group
compar
neg
control
cea
group
figur
though
often
known
cytokin
actual
pleiotrop
cytokin
antiinflammatori
immunosuppress
immunostimulatori
properti
exert
immunostimulatori
effect
b
cell
cytotox
tcell
develop
thymocyt
indic
wogensen
et
al
express
transgen
insulinproduc
pancreat
cell
led
acceler
onset
diabet
nod
mice
inhibit
immunemedi
destruct
islet
studi
moritani
et
al
nod
nonobes
diabet
mice
express
transgen
glucagonproduc
pancreat
cell
also
develop
acceler
diabet
consequ
express
model
may
exert
effect
also
effect
gener
cea
antigen
induc
respons
wherea
addit
sar
fragment
help
induc
enhanc
respons
famou
antitumor
effect
although
respons
report
autolog
tumor
tcell
patient
indol
nonhodgkin
lymphoma
frequent
exhibit
activ
apoptosispron
phenotyp
may
seem
respons
might
downregul
effect
respons
contribut
less
antitumor
activ
antitumor
immun
also
observ
model
report
chu
et
al
dna
vaccin
compris
modifi
core
peptid
pdtrp
gmcsf
code
sequenc
cterminu
induc
better
protect
tumor
challeng
protect
correl
type
immun
respons
manifest
increas
antibodi
ratio
greater
induct
mrna
tbet
mrna
spleen
cell
vaccin
mice
enhanc
sarsfragmentcontain
treatment
group
inde
display
better
immunoact
protect
effect
mice
comparison
neg
control
group
signific
differ
tumor
volum
observ
mice
immun
cea
alon
tumor
volum
found
smaller
pceasarscov
group
protect
therapi
assay
figur
result
may
indic
enhanc
affin
antigen
present
predict
algorithm
increas
immunogen
ceasar
peptid
studi
demonstr
potenti
strategi
overcom
tradit
obstacl
taaspecif
tumor
therapi
shown
possibl
foreign
sar
fragment
improv
antitumor
efficaci
tumor
vaccin
endogen
tumor
antigen
applic
kind
highlyimmunogen
peptid
enhanc
peptid
affin
predict
softwar
could
serv
platform
elicit
power
host
immun
elimin
tumor
growth
cell
line
obtain
american
type
cultur
collect
va
usa
mous
colon
cell
atcc
mous
retroviruspackag
cell
line
atcc
mous
embryo
fibroblast
atcc
cultur
rpmi
media
supplement
mm
lglutamin
penicillinstreptomycin
ps
heatinactiv
fetal
bovin
serum
fb
biolog
industri
haemek
israel
cell
gener
transfect
retrovir
vector
pmscv
neo
carri
cea
dna
fragment
ncbi
access
nucleotid
nt
bp
transfect
cell
obtain
protech
taiwan
select
maintain
rpmi
growth
medium
describ
fragment
deriv
sar
coronaviru
sarscov
ncbi
access
prove
effect
elicit
secret
human
select
use
studi
fuse
cea
lowimmunogen
peptid
peptidebind
predict
syfpeithi
score
system
util
predict
affin
cea
ceasarscov
peptid
toward
bind
balbc
molecul
eukaryot
express
plasmid
paavmc
chosen
gene
insert
express
control
cmv
promot
gene
fragment
contain
cea
sarscov
artifici
synthes
polymeras
chain
reaction
pcr
use
seri
sens
antisens
primer
design
precis
accord
two
gene
sequenc
tabl
provid
suitabl
restrict
enzym
site
antisens
sequenc
overlap
sens
sequenc
bp
design
primer
basepair
cea
fragment
restrict
enzym
site
ecori
xbai
paavmc
digest
ecori
xbai
ligat
form
pcea
sar
fragment
xbai
hindiii
pcea
digest
xbai
hindiii
ligat
form
pceasarscov
plasmid
electropor
salmonella
vaccin
vector
typhimurium
strain
mf
kv
msec
quantif
bacteria
perform
plate
serial
dilut
lb
plate
sixeightweekold
femal
balbc
mice
purchas
nation
laboratori
center
taipei
taiwan
hous
temperatur
lightcontrol
environ
anim
mainten
facil
nation
chiao
tung
univers
nctu
hsinchu
taiwan
institut
anim
care
use
committe
nctu
approv
studi
start
mice
treatment
group
immun
attenu
typhimurium
pb
transform
differ
vector
pcea
pceasarscov
three
time
two
week
neg
control
group
fed
pb
alon
evalu
cytokin
profil
mice
immun
pcea
pceasarscovtransform
typhimurium
sera
sampl
collect
day
assay
express
standard
elisa
r
mn
usa
complianc
manufactur
instruct
vaccin
protect
assay
balbc
mice
immun
use
protocol
describ
previou
section
one
week
last
booster
inject
mice
inocul
cell
tumor
growth
pattern
measur
everi
day
tumor
volum
calcul
use
formula
volum
length
width
height
evalu
tumor
therapi
balbc
mice
inocul
cell
pbsmous
oral
immun
typhimurium
pbsmous
day
later
follow
reimmun
week
first
inject
result
express
mean
se
student
test
appli
compar
effect
treatment
differ
group
mantelcox
signific
test
employ
analyz
surviv
rate
valu
p
consid
signific
author
manuscript
declar
signific
compet
financi
profession
person
interest
might
influenc
perform
present
work
describ
manuscript
kwl
csl
conceiv
studi
aim
design
contribut
systemat
review
data
extract
perform
analysi
interpret
result
shk
draft
manuscript
perform
experi
ycc
chl
yth
sci
assist
experi
cjw
rpl
contribut
revis
manuscript
author
read
approv
final
version
paper
